A modern approach to the treatment of plaque psoriasis
Psoriasis is a common chronic inflammatory skin disease which affects 0.5–1 % of children and 2–3 % of the adult population. In Croatia, 1.6 % of the population suffer from psoriasis. Distribution of the disease is bimodal, with the first peak at the age of 20–30, and the second at the age of 50–60....
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Sciendo
2019-12-01
|
| Series: | Acta Pharmaceutica |
| Subjects: | |
| Online Access: | https://doi.org/10.2478/acph-2019-0047 |
| _version_ | 1819034152786198528 |
|---|---|
| author | Drvar Daniela Ledić Vlahinić Tomislav Maleš Željan Turčić Petra Čeović Romana |
| author_facet | Drvar Daniela Ledić Vlahinić Tomislav Maleš Željan Turčić Petra Čeović Romana |
| author_sort | Drvar Daniela Ledić |
| collection | DOAJ |
| description | Psoriasis is a common chronic inflammatory skin disease which affects 0.5–1 % of children and 2–3 % of the adult population. In Croatia, 1.6 % of the population suffer from psoriasis. Distribution of the disease is bimodal, with the first peak at the age of 20–30, and the second at the age of 50–60. The etiopathogenesis of the disease is multifactorial, the key factors being genetic predisposition combined with immunological disorders, environmental factors and skin barrier damage. There are several clinical variants of the disease. The main signalling pathways in psoriasis include TNF-α, IL-23 and IL-17. Topical agents are used for the treatment of the mild form, and the systemic conventional therapy is used for the treatment of moderate to severe forms of the disease. In cases where’s no response, or intolerance or contraindications are present, new targeted medications are to be administered. Development in the field of immunogenetics of psoriasis leads to personalized medicine. |
| first_indexed | 2024-12-21T07:29:12Z |
| format | Article |
| id | doaj.art-c93420ffab4049e1af5229de79c37534 |
| institution | Directory Open Access Journal |
| issn | 1846-9558 |
| language | English |
| last_indexed | 2024-12-21T07:29:12Z |
| publishDate | 2019-12-01 |
| publisher | Sciendo |
| record_format | Article |
| series | Acta Pharmaceutica |
| spelling | doaj.art-c93420ffab4049e1af5229de79c375342022-12-21T19:11:37ZengSciendoActa Pharmaceutica1846-95582019-12-0169451152310.2478/acph-2019-0047acph-2019-0047A modern approach to the treatment of plaque psoriasisDrvar Daniela Ledić0Vlahinić Tomislav1Maleš Željan2Turčić Petra3Čeović Romana4Department of Dermatology and Venereology, University Hospital Centre Zagreb, School of Medicine, University of Zagreb, HR-10000Zagreb, CroatiaDepartment of Infectious Diseases and Dermatovenereology, Dubrovnik General Hospital, HR-20000Dubrovnik, CroatiaUniversity of Zagreb, Faculty of Pharmacy and Biochemistry, Department of Pharmaceutical Botany, HR-10000Zagreb, CroatiaUniversity of Zagreb, Faculty of Pharmacy and Biochemistry, Department of Pharmacology, HR-10000Zagreb, CroatiaDepartment of Dermatology and Venereology, University Hospital Centre Zagreb, School of Medicine, University of Zagreb, HR-10000Zagreb, CroatiaPsoriasis is a common chronic inflammatory skin disease which affects 0.5–1 % of children and 2–3 % of the adult population. In Croatia, 1.6 % of the population suffer from psoriasis. Distribution of the disease is bimodal, with the first peak at the age of 20–30, and the second at the age of 50–60. The etiopathogenesis of the disease is multifactorial, the key factors being genetic predisposition combined with immunological disorders, environmental factors and skin barrier damage. There are several clinical variants of the disease. The main signalling pathways in psoriasis include TNF-α, IL-23 and IL-17. Topical agents are used for the treatment of the mild form, and the systemic conventional therapy is used for the treatment of moderate to severe forms of the disease. In cases where’s no response, or intolerance or contraindications are present, new targeted medications are to be administered. Development in the field of immunogenetics of psoriasis leads to personalized medicine.https://doi.org/10.2478/acph-2019-0047psoriasistopical treatmentconventional systemic therapysmall moleculesbiologicals |
| spellingShingle | Drvar Daniela Ledić Vlahinić Tomislav Maleš Željan Turčić Petra Čeović Romana A modern approach to the treatment of plaque psoriasis Acta Pharmaceutica psoriasis topical treatment conventional systemic therapy small molecules biologicals |
| title | A modern approach to the treatment of plaque psoriasis |
| title_full | A modern approach to the treatment of plaque psoriasis |
| title_fullStr | A modern approach to the treatment of plaque psoriasis |
| title_full_unstemmed | A modern approach to the treatment of plaque psoriasis |
| title_short | A modern approach to the treatment of plaque psoriasis |
| title_sort | modern approach to the treatment of plaque psoriasis |
| topic | psoriasis topical treatment conventional systemic therapy small molecules biologicals |
| url | https://doi.org/10.2478/acph-2019-0047 |
| work_keys_str_mv | AT drvardanielaledic amodernapproachtothetreatmentofplaquepsoriasis AT vlahinictomislav amodernapproachtothetreatmentofplaquepsoriasis AT maleszeljan amodernapproachtothetreatmentofplaquepsoriasis AT turcicpetra amodernapproachtothetreatmentofplaquepsoriasis AT ceovicromana amodernapproachtothetreatmentofplaquepsoriasis AT drvardanielaledic modernapproachtothetreatmentofplaquepsoriasis AT vlahinictomislav modernapproachtothetreatmentofplaquepsoriasis AT maleszeljan modernapproachtothetreatmentofplaquepsoriasis AT turcicpetra modernapproachtothetreatmentofplaquepsoriasis AT ceovicromana modernapproachtothetreatmentofplaquepsoriasis |